Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTL201 (PhytoTech Therapeutics)
- Development stage
- Phase 3
- Lead developer
- Delivra
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PTL201 is an oral formulation of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) developed by PhytoTech Therapeutics, a subsidiary of Harvest One Cannabis. The drug employs a proprietary Pro-Nano Liposphere (PNL) delivery technology, which is a self-emulsifying drug delivery system (SEDDS) designed to overcome the poor oral bioavailability and high first-pass metabolism typically associated with cannabinoids. By forming a nano-emulsion in the gastrointestinal tract, the PNL system facilitates lymphatic absorption, potentially leading to more predictable and higher plasma concentrations compared to conventional oral or buccal delivery methods. PTL201 was primarily investigated in Phase II clinical trials for the treatment of spasticity and related symptoms in patients with multiple sclerosis (MS), where it was compared to the approved buccal spray Sativex.
- Other names
- THC/CBD oral capsulePhytoTech MS drug
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on PTL201 (PhytoTech Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTL201 (PhytoTech Therapeutics).